
A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is
2 amended by amending subsections (f) and (g) to read as follows:
3 "(f) Stimulants. Unless specifically excepted or unless
4 listed in another schedule, any material, compound, mixture, or
5 preparation which contains any quantity of the following
6 substances having a stimulant effect on the central nervous
7 system, including its salts, isomers, and salts of isomers:
8 (1) Aminorex;
9 (2) Cathinone;
10 (3) Fenethylamine;
11 (4) Methcathinone;
12 (5) N-ethylamphetamine;
13 (6) 4-methylaminorex;
14 (7) N,N-dimethylamphetamine; and
15 (8) Substituted cathinones, any compound, except bupropion
16 or compounds listed under a different schedule,
17 structurally derived from 2-aminopropan-1-one by



1 substitution at the 1-position with either phenyl,
2 naphthyl, or thiophene ring systems, whether or not
3 the compound is further modified in any of the
4 following ways:

- 5 (A) By substitution in the ring system to any extent
6 with alkyl, alkylendioxy, alkoxy, haloalkyl,
7 hydroxyl, or halide substituents, whether or not
8 further substituted in the ring system by one or
9 more other univalent substituents;
- 10 (B) By substitution at the 3-position with an acyclic
11 alkyl substituent; or
- 12 (C) By substitution at the 2-amino nitrogen atom with
13 alkyl, dialkyl, benzyl, or methoxybenzyl groups,
14 or by inclusion of the 2-amino nitrogen atom in a
15 cyclic structure.

16 Some other trade names: Mephedrone (2-methylamino-1-
17 p-tolylpropan-1-one), also known as 4-
18 methylmethcathinone (4-MMC), methylephedrone or MMCAT;
19 Methylenedioxyprovalerone (MDPV, MDPK); methylone or
20 3,4-methylenedioxymethcathinone; and 1-
21 (benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one,



1 monohydrochloride, also known as Ethylone, bk-MDEA
2 hydrochloride, MDEC; 3,4-Methylenedioxy-N-
3 ethylcathinone; bk-Methylenedioxyethylamphetamine [-],
4 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-
5 pyrrolidinopropiophenone (4-MePPP); alpha-
6 pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-
7 benzodioxol-5-yl)-2-(methylamino)butan-1-one
8 (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-
9 1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-
10 (methylamino)pentan-1-one (pentylone, bk-MBDP); 4-
11 fluoro-N-methylcathinone (4-FMC, flephedrone); 3-
12 fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-
13 2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-
14 pyrrolidinobutiophenone ([alpha]-PBP) and their
15 optical, positional, and geometric isomers, salts and
16 salts of isomers, whenever the existence of such
17 salts, isomers, and salts of isomers is possible.

18 (g) Any of the following cannabinoids, their salts,
19 isomers, and salts of isomers, unless specifically excepted,
20 whenever the existence of these salts, isomers, and salts of
21 isomers is possible within the specific chemical designation:



- 1 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
2 naturally contained in a plant of the genus Cannabis
3 (cannabis plant), as well as synthetic equivalents of
4 the substances contained in the plant, or in the
5 resinous extractives of Cannabis, sp. or synthetic
6 substances, derivatives, and their isomers with
7 similar chemical structure and pharmacological
8 activity to those substances contained in the plant,
9 such as the following: Delta 1 cis or trans
10 tetrahydrocannabinol, and their optical isomers; Delta
11 6 cis or trans tetrahydrocannabinol, and their optical
12 isomers; and Delta 3,4 cis or trans-
13 tetrahydrocannabinol, and its optical isomers (since
14 nomenclature of these substances is not
15 internationally standardized, compounds of these
16 structures, regardless of numerical designation of
17 atomic positions, are covered);
- 18 (2) Naphthoylindoles; meaning any compound containing a 3-
19 (1-naphthoyl)indole structure with substitution at the
20 nitrogen atom of the indole ring by a alkyl,
21 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,



- 1 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
2 morpholinyl)ethyl group, whether or not further
3 substituted in the indole ring to any extent and
4 whether or not substituted in the naphthyl ring to any
5 extent;
- 6 (3) Naphthylmethylindoles; meaning any compound containing
7 a 1H-indol-3-yl-(1-naphthyl) methane structure with
8 substitution at the nitrogen atom of the indole ring
9 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
10 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
11 2-(4-morpholinyl) ethyl group whether or not further
12 substituted in the indole ring to any extent and
13 whether or not substituted in the naphthyl ring to any
14 extent;
- 15 (4) Naphthoylpyrroles; meaning any compound containing a
16 3-(1-naphthoyl)pyrrole structure with substitution at
17 the nitrogen atom of the pyrrole ring by a alkyl,
18 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
19 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
20 ethyl group whether or not further substituted in the



- 1 pyrrole ring to any extent, whether or not substituted
2 in the naphthyl ring to any extent;
- 3 (5) Naphthylmethylenes; meaning any compound containing
4 a naphthylideneindene structure with substitution at
5 the 3-position of the indene ring by a alkyl,
6 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
8 ethyl group whether or not further substituted in the
9 indene ring to any extent, whether or not substituted
10 in the naphthyl ring to any extent;
- 11 (6) Phenylacetylindoles; meaning any compound containing a
12 3-phenylacetylindole structure with substitution at
13 the nitrogen atom of the indole ring by a alkyl,
14 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
16 ethyl group whether or not further substituted in the
17 indole ring to any extent, whether or not substituted
18 in the phenyl ring to any extent;
- 19 (7) Cyclohexylphenols; meaning any compound containing a
20 2-(3-hydroxycyclohexyl) phenol structure with
21 substitution at the 5-position of the phenolic ring by



- 1 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
2 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
3 2-(4-morpholinyl) ethyl group whether or not
4 substituted in the cyclohexyl ring to any extent;
- 5 (8) Benzoylindoles; meaning any compound containing a 3-
6 (benzoyl) indole structure with substitution at the
7 nitrogen atom of the indole ring by a alkyl,
8 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
10 morpholinyl) ethyl group whether or not further
11 substituted in the indole ring to any extent and
12 whether or not substituted in the phenyl ring to any
13 extent;
- 14 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
15 pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
16 naphthalenylmethanone (another trade name is WIN
17 55,212-2);
- 18 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
19 methyloctan-2-yl)-6a,7,10,10a-
20 tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
21 HU-210/HU-211);



- 1 (11) Tetramethylcyclopropanoylindoles; meaning any compound
2 containing a 3-tetramethylcyclopropanoylindole
3 structure with substitution at the nitrogen atom of
4 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
5 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
6 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
7 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
8 morpholinyl)methyl, or tetrahydropyranylmethyl group,
9 whether or not further substituted in the indole ring
10 to any extent and whether or not substituted in the
11 tetramethylcyclopropyl ring to any extent;
- 12 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
13 its optical, positional, and geometric isomers, salts,
14 and salts of isomers (Other names: APINACA, AKB48);
- 15 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
16 optical, positional, and geometric isomers, salts, and
17 salts of isomers (Other names: PB-22; QUPIC);
- 18 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
19 carboxylate, its optical, positional, and geometric
20 isomers, salts, and salts of isomers (Other names: 5-
21 fluoro-PB-22; 5F-PB-22);



- 1 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
2 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
3 positional, and geometric isomers, salts, and salts of
4 isomers (Other names: AB-FUBINACA);
- 5 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
6 indazole-3-carboxamide, its optical, positional, and
7 geometric isomers, salts, and salts of isomers (Other
8 names: ADB-PINACA);
- 9 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
10 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its
11 optical, positional, and geometric isomers, salts, and
12 salts of isomers (Other names: AB-CHMINACA);
- 13 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
14 indazole-3-carboxamide, and geometric isomers, salts,
15 and salts of isomers (Other names: AB-PINACA);
- 16 (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
17 yl)methanone, and geometric isomers, salts, and salts
18 of isomers (Other names: THJ-2201);
- 19 (20) Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-
20 valinate, and geometric isomers, salts, and salts of
21 isomers (Other names: FUB-AMB);



- 1 (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
2 carboxamido)-3-methylbutanoate, and geometric isomers,
3 salts, and salts of isomers (Other names: 5-fluoro-
4 AMB, 5-fluoro-AMP);
- 5 (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
6 indazole-3-carboxamide, and geometric isomers, salts,
7 and salts of isomers (Other names: AKB48 N-(5-
8 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
9 analog, 5F-APINACA);
- 10 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
11 geometric isomers, salts, and salts of isomers (Other
12 names: STS-135, 5F-APICA; 5-fluoro-APICA);
- 13 (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
14 carboxylate, and geometric isomers, salts, and salts
15 of isomers (Other names: NM2201);
- 16 (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
17 (cyclohexylmethyl)-1H-indazole-3-carboxamide, and
18 geometric isomers, salts, and salts of isomers (Other
19 names: MAB-CHMINACA and ADB-CHMINACA); [~~and~~]
- 20 (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
21 carboxamido]-3,3-dimethylbutanoate (Other names: 5F-



1 ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
2 positional, and geometric isomers, salts, and salts of
3 isomers [\pm]; and

4 (27) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
5 carboxamide (CUMYL-4CN-BINACA), its optical,
6 positional, and geometric isomers, salts and salts of
7 isomers; also known as SGT-78, 4-CN-CUMYL-BINACA;
8 CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL-
9 BUTINACA."

10 SECTION 2. Section 329-16, Hawaii Revised Statutes, is
11 amended by amending subsection (g) to read as follows:

12 "(g) Hallucinogenic substances, unless listed in another
13 schedule, shall include:

- 14 (1) Nabilone [\pm]; and
- 15 (2) Dronabinol (-)-delta-9-trans tetrahydrocannabinol in
16 an oral solution in a drug product approved for
17 marketing by the U.S. Food and Drug Administration."

18 SECTION 3. Statutory material to be repealed is bracketed
19 and stricken. New statutory material is underscored.

20 SECTION 4. This Act shall take effect on July 1, 3000.



Report Title:

Uniform Controlled Substances Act

Description:

Updates chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal Controlled Substances Act as required under section 329-11. (HB2385 HD2)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

